TAILIEUCHUNG - Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study

Trastuzumab and fulvestrant combination therapy is one of the treatment options for patients with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer; however, there are limited studies evaluating the efficacy of this combination therapy. | Ozaki et al. BMC Cancer 2022 22 36 https s12885-021-09128-1 RESEARCH Open Access Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2 a retrospective single-center study Yukinori Ozaki1 2 Yosuke Aoyama3 Jun Masuda1 Lina Inagaki1 Saori Kawai1 Tomoko Shibayama1 Tetsuyo Maeda1 Mami Kurata1 Kazuyo Yoshida1 Sumito Saeki1 Mari Hosonaga1 Ippei Fukada1 Fumikata Hara1 Takayuki Kobayashi1 Kokoro Kobayashi1 Satoshi Miyake2 Toshimi Takano1 Takayuki Ueno1 and Shinji Ohno1 Abstract Background Trastuzumab and fulvestrant combination therapy is one of the treatment options for patients with hormone receptor- and human epidermal growth factor receptor 2 HER2 -positive metastatic breast cancer how- ever there are limited studies evaluating the efficacy of this combination therapy. Methods We retrospectively reviewed the data of women with hormone receptor- and HER2-positive metastatic breast cancer who received trastuzumab and fulvestrant combination therapy between August 1997 and August 2020 at the Cancer Institute Hospital. The primary endpoint of this study was progression-free survival and the sec- ondary endpoints were response rate overall survival and safety. Results We reviewed the data of 1612 patients with recurrent or metastatic breast cancer of which 118 patients were diagnosed with hormone receptor- and HER2-positive breast cancer. Of these 28 patients who received tras- tuzumab and fulvestrant combination therapy were eligible for this study. The median treatment line for advanced breast cancer was 6 range 1 14 the median progression-free survival was months 95 confidence interval CI and the median overall survival was months 95 CI . Of the 28 patients partial response was observed in 1 4 stable disease in 17 61 and progressive disease in 10 36 patients. The disease control rate was 64 . Adverse events of grade 3 .

• Y khoa - Dược
• BMC Cancer
• Hormone receptor positive HER2 positive breast cancer
• Combination therapy
• Fulvestrant combination therapy
• HER2 expression
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study